Vator Securities: No one-trick pony – advancing a novel platform-based CNS company

AlzeCure has with its seven-project portfolio multiple shots at goal where each, while early stage, represents a potential multibillion-dollar opportunity. It goes without saying that the past year’s achievements mark management’s extensive experience and competence in drug development and how to sophisticatedly run a research and development company. This is an important asset to recognize, and it should provide the market confidence in the company’s ability to drive the company successfully forward and limit the risk-profile to biological risk factors. By leveraging its solid